TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01568216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 747
Description: Three dose levels once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 747
Description: Three dose levels once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 747
Description: Three dose levels once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study: NCT04207398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunts
Description: Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)
Description: Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
Study: NCT03702608

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: EluNIR Ridaforolimus Eluting Coronary Stent System
Description: The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~* Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~* Delivery System - Rapid Exchange (RX) Coronary System~* Polymer matrix coating - (PBMA) and CarboSil®~* Ridaforolimus drug
Study: NCT05468879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl®
Description: Amaryl®
Study: NCT03552718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YE-NEO-001
Description: Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
Study: NCT01938859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuganjieyu capsule
Description: Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
Study: NCT02786641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 65mg/m2 in induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 1
Description: Cisplatin 75mg/m2 in induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda 2000mg/m2 D1-14 in induction chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT for all patients

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT for all patients

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT for all patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 2
Description: Cisplatin 100mg/m2 in concurrent chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 2
Description: Cisplatin 100mg/m2 in concurrent chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 2
Description: Cisplatin 100mg/m2 in concurrent chemotherapy
Study: NCT04972383

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: In the Hyaluronic group, 3mLHYAJOINT Plus was given.
Study: NCT03487224

Intervention type: DEVICE
Intervention: MRI with fMRI frequency
Description: Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.

Intervention type: DEVICE
Intervention: MRI with fMRI frequency
Description: Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
Study: NCT02983084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic archwire
Description: Archwire used to align teeth in an orthodontic fixed appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic archwire
Description: Archwire used to align teeth in an orthodontic fixed appliance
Study: NCT00730990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission tomography
Description: Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET Scan with PF-03654746
Description: If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
Study: NCT02983084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic archwire
Description: Archwire used to align teeth in an orthodontic fixed appliance
Study: NCT04237649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAZ954
Description: KAZ954 will be administered in every arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAZ954
Description: KAZ954 will be administered in every arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAZ954
Description: KAZ954 will be administered in every arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAZ954
Description: KAZ954 will be administered in every arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: KAZ954 + PDR001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: KAZ954 + NIR178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NZV930
Description: KAZ954 + NZV930
Study: NCT00942162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2132231A
Description: Intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2132231A
Description: Intramuscular administration
Study: NCT00730990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET Scan with PF-03654746
Description: If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET Scan with PF-03654746
Description: Part 2 of the study will have 3 possible interventions:~1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg).
Study: NCT03847779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: Cutaneous perfusion and vasomotion assessment at rest in supoine position
Study: NCT02917525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03777826

Intervention type: OTHER
Group type: OTHER
Intervention: PKU Synergy
Description: PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
Study: NCT02460653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC Flow Rate
Description: We only change the flow rates between low, medium and high settings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC Flow Rate
Description: We only change the flow rates between low, medium and high settings.
Study: NCT04325789

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nanofiber scaffold
Description: Utilization of the interpositional nanofiber scaffold to augment the rotator cuff repair.
Study: NCT03724747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2315497 Injection
Description: BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2315497 Injection
Description: BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2315497 Injection
Description: BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2315497 Injection
Description: BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide(BAY1841788)
Description: 600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
Study: NCT06526468

Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results

Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results

Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results

Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results
Study: NCT01419067

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical Surgery or Limited Surgery
Description: Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.

Intervention type: DEVICE
Group type: OTHER
Intervention: Proton Therapy
Description: Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: ^1^8F-fluorodeoxyglucose
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.

Intervention type: DRUG
Group type: OTHER
Intervention: ^1^1C-methionine
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Study: NCT00942162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2132231A
Description: Intramuscular administration
Study: NCT03941444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Description: Liquid oral solution
Study: NCT02460653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC Flow Rate
Description: We only change the flow rates between low, medium and high settings.
Study: NCT01730638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: • TF2 and 68 Ga-IMP-288
Study: NCT03847779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: Cutaneous perfusion and vasomotion assessment at rest in supoine position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: Cutaneous perfusion and vasomotion assessment at rest in supoine position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot lowering
Description: Cutaneous perfusion and vasomotion assessment after foot lowering

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot lowering
Description: Cutaneous perfusion and vasomotion assessment after foot lowering

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot lowering
Description: Cutaneous perfusion and vasomotion assessment after foot lowering

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Cutaneous perfusion and vasomotion assessment during hyperthermia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Cutaneous perfusion and vasomotion assessment during hyperthermia
Study: NCT03941444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid oral solution
Study: NCT02833311

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Tablet Group
Description: A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
Study: NCT03847779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Cutaneous perfusion and vasomotion assessment during hyperthermia
Study: NCT00437125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
Study: NCT02833311

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper and Pencil Group
Description: Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact Control Group
Description: Participants are prescribed an exercise program and given information on healthy eating.
Study: NCT00509886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drysol
Description: 20% aluminum chloride hexahydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drioff
Description: 1% aluminum acetate
Study: NCT01823562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lyophilized black raspberry confection
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lyophilized black raspberry confection
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lyophilized black raspberry confection
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lyophilized black raspberry confection
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: Follow a low polyphenol diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: Follow a low ellagitannin diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Follow a low ellagitannin diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Follow a low ellagitannin diet
Study: NCT04196335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-procedural intracardiac echocardiography
Description: use of intra-procedural intracardiac echocardiography during Watchman FLX devices
Study: NCT03936101

Intervention type: DIAGNOSTIC_TEST
Intervention: Prenatal Genomic Sequencing
Description: Whole genome sequencing (which initially will be masked and reported as exome only)
Study: NCT03208374

Intervention type: BEHAVIORAL
Intervention: Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire
Description: Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.

Intervention type: BEHAVIORAL
Intervention: Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)
Description: The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
Study: NCT03824691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: cabozantinib 40 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg durvalumab (MEDI4736) IV infusion every 28 days
Study: NCT02561845

Intervention type: DRUG
Intervention: rosuvastatin
Description: 5mg, 10mg, 20mg
Study: NCT01823562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Follow a low ellagitannin diet
Study: NCT00032487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2